Literature DB >> 6409008

[Cancer chemotherapy in combination with angiotensin-induced hypertension].

A Wakui, M Suzuki.   

Abstract

It was observed experimentally that rise of the mean arterial blood pressure to about mmHg by angiotensin II resulted in a marked increase in blood flow in tumor tissue without increasing blood flow in normal tissue, such as the liver, brain, bone marrow and subcutis. This result clearly indicated the lack of autoregulation of blood flow in tumor tissue. Considering the physiological characteristics of microcirculation in tumor, it is possible to selectively increase tumor blood flow without affecting blood flow in normal tissues. This finding could be applied to cancer chemotherapy for enhancing drug delivery to tumor tissue selectively. Thus, based on these experimental results, clinical studies have been performed in 86 patients with various advanced cancers. Among 72 evaluable patients, there are 8 complete and 26 partial responders with an overall response rate of 47.2%. Nine of 19 patients with gastric cancer responded to the therapy. The clinical procedure and apparatus using in this treatment were described together with technical precaution.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6409008

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Functional characterization of the microcirculation in tumors.

Authors:  M Suzuki; K Hori; I Abe; S Saito; H Sato
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

Review 2.  Some aspects of size-dependent differential drug response in primary and metastatic tumors.

Authors:  I Abe; M Suzuki; K Hori; S Saito; H Sato
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

3.  Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumours.

Authors:  N P Rowell; V R McCready; D Tait; M A Flower; B Cronin; G E Adams; A Horwich
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.